Efficacy of intravitreal Ranibizumab injection for choroidal neovascularization secondary to pathologic myopia

• Main Authors: Li-Hong Cui, Zhi Yang, Li Xu
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2016-03-01
• Series: Guoji Yanke Zazhi
• Subjects: choroidal neovascularization; drug therapy; myopia; degenerative; antibodies; monoclonal
• Online Access: http://ies.ijo.cn/cn_publish/2016/3/201603034.pdf

AIM:To observe the efficacy and safety of intravitreal Ranibizumab injection in patiens with choroidal neovascularization(CNV)secondary to pathologic myopia.<p>METHODS:In this retrospective and comparative study,24 patients(25 eyes)with CNV secondary to pathologic myopia were enrolled. All patients were assessed by examinations of ETDRS visual acuity chart, preplaced-mirror ophthalmoscopy, fundus fluorescein angiography(FFA), indocyanine green angiography(ICGA)and optical coherence tomography(OCT). Patiens received intravitreally injected ranibizumab 0.5mg(0.05mL). Treatments were repeated if the follow-up indicated that it was necessary. The follow-up periods were 4～10mo. Best corrected visual acuity(BCVA), central macular thickness(CMT)and leakage of CNV before and after the treatment were compared. <p>RESULTS:No local or systemic complications occurred in any patients during the treatment or follow-up. The average time of injection was 1.52. The mean BCVA was 23.93±12.46 letters before the therapy. In the last follow-up, the mean BCVA was 40.63±7.25 letters, improved by 14.27±9.36 letters and the difference was statically significant(<i>t</i>=5.74, <i>P</i><0.05). The mean CMT was 363.47±119.62μm before treatments and 190.31±37.02μm after treatments which was 72.82±60.57 μm less than the pre-treatment values and the difference was statically significant(<i>t</i>=3.96, <i>P</i><0.05). <p>CONCLUSION:Intravitreal ranibizumab injection for CNV secondary to pathologic myopia is safe and effective, and this treatment can improve visual acuity, reduce retina edema and leakage of CNV.